ViiV Healthcare - Articles and news items

ViiV Healthcare to evaluate injectable HIV treatment

Industry news / 23 November 2016 / Niamh Louise Marriott, Digital Content Producer

The two studies, FLAIR and ATLAS, will examine the safety and efficacy of monthly dosing with the two-drug, injectable regimen in both treatment-naïve…

Global dual-drug trial aims to advance HIV treatment

Industry news / 16 August 2016 / ViiV Healthcare

ViiV Healthcare is undertaking two identical studies as part of a global phase III programme comparing a two-drug regimen of dolutegravir plus lamivudine, with a three-drug regimen of dolutegravir (Tivicay), plus the fixed-dose tablet tenofovir/emtricitabine (Truvada), to support regulatory filings as a treatment for HIV, for adults who have had no prior antiretroviral therapy…

Triumeq demonstrates superior efficacy for treating women with HIV

Industry news / 19 July 2016 / Victoria White, Digital Content Producer

Triumeq demonstrated superior efficacy compared with ATV/r plus TDF/FTC in 495 treatment-naïve women living with HIV…

From HIV to oncology: widening access through flexible IP

Blog, Z Homepage promo / 28 April 2016 / Jon Pender, VP Government Affairs, GSK

Jon Pender, GSK, discusses how a flexible and thoughtful approach to IP can help get medicines to the poorest and hardest-to-reach patients around the world…

ViiV and Janssen progress two drug injectable HIV-1 treatment

Industry news / 8 January 2016 / Victoria White

ViiV Healthcare has formalised its collaboration with Janssen for the Phase III investigation and commercialisation of the injectable formulations of cabotegravir and rilpivirine…

BMS divests its HIV R&D assets to ViiV Healthcare

Industry news / 18 December 2015 / Victoria White

ViiV will pay to Bristol-Myers Squibb upfront payments totaling $350 million with potential development and regulatory milestone payments of up to $518 million for the clinical assets and up to $587 million for the discovery and preclinical programmes…

Results announced for two drug injectable regimen for HIV maintenance therapy

Industry news / 3 November 2015 / Victoria White

Results from the study show that cabotegravir and rilpivirine were comparable in maintaining viral suppression rates to a three drug oral regimen…

Switching to once-daily Triumeq maintains HIV viral suppression

Industry news / 23 September 2015 / Victoria White

A Phase IIIb/IV study demonstrated that viral suppression was non-inferior for patients switching to once-daily Triumeq from an antiretroviral therapy…

ViiV Healthcare and Desano manufacturing agreement will bring competitive supply of dolutegravir to China

Industry news / 3 July 2015 / Victoria White

ViiV Healthcare and Desano Pharmaceuticals have announced a strategic manufacturing agreement to enable production of dolutegravir in China…

ViiV Healthcare Logo

ViiV Healthcare announces new grants in support of ending mother to child transmission of HIV

Industry news / 27 November 2014 / ViiV Healthcare

Landmark number of grants awarded for 2015 as the Positive Action for Children Fund hits 5 year milestone…

ViiV Healthcare Logo

ViiV Healthcare receives EU marketing authorisation for Triumeq® (dolutegravir/abacavir/lamivudine), a new once-daily single-pill regimen for the treatment of HIV

Industry news / 5 September 2014 / GlaxoSmithKline

ViiV Healthcare announced that the European Commission has granted marketing authorisation for Triumeq® (dolutegravir 50mg / abacavir 600mg / lamivudine 300mg) tablets…

GlaxoSmithKline logo

ViiV Healthcare receives FDA approval for Triumeq® (abacavir, dolutegravir and lamivudine), a new single-pill regimen for the treatment of HIV-1 infection

Industry news / 26 August 2014 / GlaxoSmithKline

ViiV Healthcare announced that the US Food and Drug Administration has approved Triumeq® (abacavir 600mg, dolutegravir 50mg and lamivudine 300mg) tablets for the treatment of HIV-1 infection…

  • Page 1 of 2
  • 1
  • 2
  • >


The deadline for submissions to the EPR Awards is 9 June 2017! Entry is FREE, so don't delay...